ATE286126T1 - Glialmitogene faktoren, ihre herstellung und verwendung - Google Patents

Glialmitogene faktoren, ihre herstellung und verwendung

Info

Publication number
ATE286126T1
ATE286126T1 AT93918139T AT93918139T ATE286126T1 AT E286126 T1 ATE286126 T1 AT E286126T1 AT 93918139 T AT93918139 T AT 93918139T AT 93918139 T AT93918139 T AT 93918139T AT E286126 T1 ATE286126 T1 AT E286126T1
Authority
AT
Austria
Prior art keywords
glialmitogenic
factors
production
molecules
encode
Prior art date
Application number
AT93918139T
Other languages
English (en)
Inventor
Andrew Goodearl
Paul Stroobant
Luisa Minghetti
Michael Waterfield
Mark Marchioni
Maio Su Chen
Ian Hiles
Original Assignee
Ludwig Inst Cancer Res
Cambridge Neuroscience Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Cambridge Neuroscience Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE286126T1 publication Critical patent/ATE286126T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
AT93918139T 1992-06-30 1993-06-29 Glialmitogene faktoren, ihre herstellung und verwendung ATE286126T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90713892A 1992-06-30 1992-06-30
US94038992A 1992-09-03 1992-09-03
US96517392A 1992-10-23 1992-10-23
US08/036,555 US5530109A (en) 1991-04-10 1993-03-24 DNA encoding glial mitogenic factors
PCT/US1993/006228 WO1994000140A1 (en) 1992-06-30 1993-06-29 Glial mitogenic factors, their preparation and use

Publications (1)

Publication Number Publication Date
ATE286126T1 true ATE286126T1 (de) 2005-01-15

Family

ID=27488375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93918139T ATE286126T1 (de) 1992-06-30 1993-06-29 Glialmitogene faktoren, ihre herstellung und verwendung

Country Status (11)

Country Link
US (8) US5530109A (de)
EP (1) EP0653940B1 (de)
JP (1) JP4127567B2 (de)
KR (2) KR100344006B1 (de)
AT (1) ATE286126T1 (de)
AU (2) AU688270B2 (de)
CA (1) CA2139136A1 (de)
DE (1) DE69333731T2 (de)
ES (1) ES2236686T3 (de)
PT (1) PT101297B (de)
WO (1) WO1994000140A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106666A1 (en) * 1991-04-10 2005-05-19 Cambridge Neuroscience Glial mitogenic factors, their preparation and use
US5716930A (en) * 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7319019B1 (en) * 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US7037888B1 (en) * 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US6087323A (en) * 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
AU693767B2 (en) * 1992-08-10 1998-07-09 Cambridge Neuroscience, Inc. Inhibitors of cell proliferation, their preparation and use
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US6750196B1 (en) * 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5670342A (en) * 1995-04-06 1997-09-23 Amgen Inc. NDF peptides
US5721139A (en) * 1995-05-10 1998-02-24 Genentech, Inc. Isolating and culturing schwann cells
US6033660A (en) * 1995-05-10 2000-03-07 Genentech, Inc. Method of treating a nervous system injury with cultured schwann cells
US5849585A (en) * 1995-05-10 1998-12-15 Genetech, Inc. Isolating and culturing Schwann cells
GB9514325D0 (en) 1995-07-13 1995-09-13 Royal Free Hosp School Med Detection and quantification of human herpes virus 7 by enzymic amplification
US5912326A (en) * 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
DK0912734T3 (da) 1996-07-12 2011-02-07 Genentech Inc Kimæriske heteromultimer-adhæsiner
CA2257839C (en) * 1996-07-12 2012-10-23 Genentech, Inc. Gamma-heregulin
US5955111A (en) * 1996-10-08 1999-09-21 Hartford Hospital Methods and compositions for inducing production of stress proteins
AU732027B2 (en) 1997-02-10 2001-04-12 Genentech Inc. Heregulin variants
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
KR20010031103A (ko) * 1997-10-14 2001-04-16 버틀러 그레고리 비. 네우레굴린을 사용하는 치료요법적 방법
WO1999031505A1 (en) * 1997-12-15 1999-06-24 Shire Laboratories Inc. Neurotrophic factor assay
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
US6110718A (en) 1998-03-20 2000-08-29 Wayne State University Mammalian putative phosphatidylinositol-4-phosphate-5-kinase
US6051401A (en) * 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6933122B1 (en) * 1999-05-14 2005-08-23 The Trustees Of Columbia University In The City Of New York A-form of cytoplasmic domain of nARIA (CRD-neuregulin) and uses thereof
US7538197B2 (en) 2000-02-11 2009-05-26 Proteosys Ag Use of neuregulin-β as an indicator and/or target
ATE461935T1 (de) * 2000-03-27 2010-04-15 Genetics Inst Llc Verfahren zur reinigung von stark anionischen proteinen
EP2357004B1 (de) * 2000-05-23 2016-10-12 CeNeS Pharmaceuticals, Inc. NRG-2-Nukleinsäuremoleküle, Polypeptide und Diagnose- und Therapieverfahren
US7824923B2 (en) * 2001-08-06 2010-11-02 Proteosys Ag Neuregulin-β isoforms associated with neuronal processes
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2005017096A2 (en) * 2003-08-19 2005-02-24 Agos Biotech Ltd. SPLICE VARIANTS OF ErbB LIGANDS, COMPOSITIONS AND USES THEREOF
TWI276685B (en) * 2003-12-30 2007-03-21 Ind Tech Res Inst Conditional medium for culturing Schwann cells
AU2005280088A1 (en) * 2004-08-27 2006-03-09 Absorbent Technologies, Inc. Superabsorbent polymers in agricultural applications
KR100680479B1 (ko) * 2005-04-11 2007-02-08 주식회사 하이닉스반도체 비휘발성 메모리 장치의 프로그램 검증 방법
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
EP1981525B1 (de) 2005-12-30 2015-01-21 Zensun (Shanghai) Science and Technology Limited Verlängerte freisetzung von neuregulin für verbesserte herzfunktion
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
US7521535B2 (en) 2006-09-20 2009-04-21 The Board Of Regents For Oklahoma State University Anti-microbial defensin-related peptides and methods of use
CA2686959C (en) 2007-05-10 2017-06-13 Acorda Therapeutics Inc. Methods for detecting cardiac damage
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
RU2491955C2 (ru) 2007-11-16 2013-09-10 МЕН-ЭнЭрЖ СА Активные растворимые изоформы нейрегулина, несущие посттрансляционные модификации
EP2262527B1 (de) * 2008-02-29 2016-08-03 Acorda Therapeutics, Inc. Zubereitungen zur erzielung erwünschter plasmaspiegel von glia-wachstumsfaktor 2
US9348975B2 (en) * 2008-05-02 2016-05-24 Baxter International Inc. Optimizing therapy outcomes for peritoneal dialysis
US8882700B2 (en) 2008-05-02 2014-11-11 Baxter International Inc. Smart patient transfer set for peritoneal dialysis
US8057679B2 (en) 2008-07-09 2011-11-15 Baxter International Inc. Dialysis system having trending and alert generation
EP3632459A1 (de) 2008-07-17 2020-04-08 Acorda Therapeutics, Inc. Therapeutische dosierung eines neuregulins oder einer subsequenz davon zur behandlung oder prophylaxe von herzversagen
EP2328606B1 (de) 2008-08-15 2016-10-05 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung in nicht-akuten phasen nach einer neurologischen cns-verletzung
EP2370093A4 (de) * 2008-11-28 2012-08-29 Zensun Shanghai Science And Technology Ltd Neuregulin und kardiale stammzellen
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
US8377012B2 (en) * 2009-01-30 2013-02-19 Baxter International Inc. Transfer sets for therapy optimization
US8282829B2 (en) 2009-05-20 2012-10-09 Baxter International Inc. System and method for automated data collection of twenty-four hour ultrafiltration and other patient parameters using wired or wireless technology
JP2013503110A (ja) 2009-06-09 2013-01-31 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンに基づく心不全の治療方法
WO2010142141A1 (en) 2009-06-09 2010-12-16 Zensun (Shanghai) Science & Technology Limited Neuregulin based methods for treating heart failure
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102596225B (zh) 2009-10-14 2015-06-24 阿寇达医疗有限公司 神经调节蛋白在治疗外周神经损伤中的应用
US9020827B2 (en) 2009-10-16 2015-04-28 Baxter International Inc. Peritoneal dialysis optimized using a patient hand-held scanning device
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US20150094263A1 (en) 2012-03-30 2015-04-02 Acorda Therapeutics, Inc. Use of Neuregulin to Treat Peripheral Nerve Injury
CN104884077B (zh) 2012-10-08 2019-02-12 上海泽生科技开发股份有限公司 治疗糖尿病患者心力衰竭的组份和方法
WO2014138502A1 (en) 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
AU2014270882B2 (en) 2013-05-22 2019-03-14 Zensun (Shanghai) Science & Technology, Co. Ltd. Extended release of neuregulin for treating heart failure
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
WO2015140351A1 (en) 2014-03-21 2015-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing myelination
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
AU2016327974A1 (en) 2015-09-25 2018-04-12 Douglas B. Sawyer Methods for treating cardiac injury
EA202092458A1 (ru) 2018-04-11 2021-02-08 Салюбрис Байотерапьютикс, Инк. Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения
CN111407881A (zh) 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
US20230057622A1 (en) 2019-09-16 2023-02-23 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant Human Neuregulin Derivatives and Use Thereof
CN113289002A (zh) 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
TW202306975A (zh) 2021-06-10 2023-02-16 美商安進公司 對ｅｒｂｂ４而非ｅｒｂｂ３具有改善的選擇性的工程化ｎｒｇ－１變體
TW202400217A (zh) 2022-03-15 2024-01-01 美商信立泰生物醫藥公司 用神經調節蛋白－１融合蛋白治療纖維化及心律不整的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US5214034A (en) * 1986-09-26 1993-05-25 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system containing the same
US5019559A (en) * 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
EP0474727B1 (de) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extrazellulare domäne
DE69126430T2 (de) * 1990-04-06 1997-09-18 Univ Pennsylvania Ligand für das neu-gen-produkt
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
CA2083688A1 (en) * 1990-05-25 1991-11-26 Marc Lippman Growth factor which inhibits the growth of cells overexpressing the human oncogene erbb-2
US5202428A (en) * 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
JPH06505011A (ja) * 1991-01-14 1994-06-09 ジョージタウン・ユニバーシティ ｅｒｂＢ−２受容体タンパク質に結合し且つ細胞性応答を誘導するリガンド成長因子
GB9107566D0 (en) * 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5237056A (en) * 1991-05-29 1993-08-17 President And Fellows Of Harvard College DNA encoding a protein which copurifies with acetylcholine receptor inducing activity and uses therefor
CA2134564A1 (en) * 1992-04-29 1993-11-11 Duanzhi Wen Recombinant stimulating factor of the neu receptor
EP0641358B1 (de) * 1992-04-29 2000-03-15 Georgetown University Bindungspeptide zur interaktion mit wachstumsfaktoren als liganden des rezeptors des epidermiswachstumsfactor und des erbb-2-rezeptor

Also Published As

Publication number Publication date
EP0653940A1 (de) 1995-05-24
US5602096A (en) 1997-02-11
US6147190A (en) 2000-11-14
US5606032A (en) 1997-02-25
JP4127567B2 (ja) 2008-07-30
WO1994000140A1 (en) 1994-01-06
PT101297A (pt) 1994-06-30
AU4833897A (en) 1998-04-23
CA2139136A1 (en) 1994-01-06
KR100307943B1 (ko) 2001-12-01
PT101297B (pt) 1999-10-29
US5854220A (en) 1998-12-29
EP0653940B1 (de) 2004-12-29
AU4769493A (en) 1994-01-24
ES2236686T3 (es) 2005-07-16
US5792849A (en) 1998-08-11
US5530109A (en) 1996-06-25
US6232286B1 (en) 2001-05-15
AU688270B2 (en) 1998-03-12
DE69333731D1 (de) 2005-02-03
KR100344006B1 (ko) 2002-12-11
EP0653940A4 (de) 1997-02-26
DE69333731T2 (de) 2006-03-09
JPH08509357A (ja) 1996-10-08
US5621081A (en) 1997-04-15

Similar Documents

Publication Publication Date Title
ATE286126T1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
DE69737507D1 (de) Neue nukleinsäuremoleküle aus mais und deren verwendung zur herstellung modifizierter stärke
DE3864585D1 (de) Dns-molekule, codierend fuer non-a-non-b-hepatitis-antigene und ihre verwendung zur herstellung dieser antigene.
DE69839768D1 (de) Rekombinante lactoferrin, verfahren zu ihrer herstellung mittels pflanzen und ihre verwendung
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
DE69312232D1 (de) Bpc-peptide, ihre herstellung und verwendung
ATE181056T1 (de) Arylessigsäurederivate und ihre verwendung als fungizide
DE69504808D1 (de) Corticotropin freisetzende rezeptoren des faktor 2
DE3853446T2 (de) Fibronectinbindungsprotein und dessen Herstellung.
DE19781038T1 (de) Keratinozytenwachstumsfaktor-2-Produkte
EP0261403A3 (de) Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle
ATE175237T1 (de) Polypeptide beteiligt an der kobalamin- und/oder kobamid-biosynthese, für diese kodierende dns- sequencen, und ihre herstellung und vewendung.
ATE61409T1 (de) Biosynthetische 2,5-diketogluconsaeurereduktase, verfahren, rekombinante zellen und expressionsvektoren fuer ihre herstellung und ihre verwendung zur bereitung von 2-keto-l-gulonsaeure.
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
ATE286968T1 (de) Isolierung und verwendung von nukleinsäuremolekülen, welche für mitglieder der ssx-familie kodieren
DE60225530D1 (de) Phosphorylierte glyoxalase i und deren verwendung
ATE99687T1 (de) Strobilurinderivate, ihre herstellung und verwendung.
ATE112319T1 (de) Klonierungs- und/oder expressionsvektoren, verfahren zur ihrer herstellung und verwendung.
DE59106119D1 (de) Stabilisatorkombinationen und ihre Verwendung zur Herstellung von stabilisierten, schlagzähmodifizierten Polyamiden.
IT8521507A0 (it) Vettore di clonaggio, molecole di dna ricombinante, ceppi di bacillus subtilis trasformati con dette molecole e metodi per l'espressione di geni eterologhi e produzione e secrezione di proteine codificate da detti geni.
DE59009360D1 (de) Für das Plazentaprotein 9 (PP9) kodierende cDNA, ihre Isolierung und Verwendung.
EP0374909A3 (de) Für das Plazentaprotein 11 (PP11) kodierende cDNA, ihre Isolierung und Verwendung
DE59905342D1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties